Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 8 |
| 1.1 List of Tables | 7 | 2 |
| 1.2 List of Figures | 9 | 2 |
| 2 Introduction and Overview | 11 | 1 |
| 2.1 In-Vitro-Diagnostics (IVD) Overview | 11 | 1 |
| 3 Global In-Vitro Diagnostics (IVD) Market: Market Characterization | 12 | 13 |
| 3.1 Global In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 12 | 1 |
| 3.2 Global In-Vitro Diagnostics (IVD) Market, Revenue Forecasts ($m), 2009 2016 | 13 | 1 |
| 3.3 Global In-Vitro Diagnostics (IVD) Market, Company Share (%), 2008 | 14 | 1 |
| 3.4 Global In-Vitro Diagnostics (IVD) Market, Key Market Trends | 15 | 1 |
| 3.4.1 Entry of Diagnostic Imaging Players into the In-Vitro Diagnostics (IVD) Market Has Set Stage for New Technologies to Be Developed By Marrying the Two Disciplines | 15 | 1 |
| 3.4.2 Large Number of Private Equity/ Venture Capital (PE/VC) Investments and Collaborations in the In-Vitro Diagnostics (IVD) Sector to Fuel Innovation | 16 | 1 |
| 3.4.3 Consolidation of Laboratories across the World | 16 | 1 |
| 3.5 Global In-Vitro Diagnostics (IVD) Market: Key Technology Trends | 17 | 1 |
| 3.5.1 Emerging Technologies for Cutting Lab Costs | 17 | 1 |
| 3.5.1.1 Point of Care Testing (POCT) Technology | 17 | 1 |
| 3.5.1.2 Automation | 18 | 1 |
| 3.5.2 New Technologies Improve Speed and Accuracy | 18 | 1 |
| 3.5.2.1 Advanced Technologies Such As Miniaturization of Rapids Tests Expand Use of POCT to Critical Care and Emergency Medicine | 18 | 1 |
| 3.5.2.2 Growth of Molecular Diagnostics Is Facilitating Early Disease Detection | 18 | 1 |
| Rising Emphasis on Patient Centric, Personalized Medicine to Accelerate Development of Companion Diagnostics | 19 | 1 |
| 3.6 Global In-Vitro Diagnostics (IVD) Market, Market Drivers | 20 | 1 |
| 3.6.1 Economic Market Drivers | 20 | 1 |
| 3.6.1.1 Emerging Countries to Play an Important Role in Driving Growth | 20 | 1 |
| 3.6.1.2 Need to Control Costs at Laboratories to Drive Adoption of New Processes and Instruments | 20 | 1 |
| 3.6.1.3 Retail Testing Services Will Have a Positive Impact on In-Vitro Diagnostics (IVD) Market, As Accessibility to the Common Man Improves | 21 | 1 |
| 3.6.2 Technological Market Drivers | 22 | 1 |
| 3.6.2.1 Growth in New Technologies Such As Molecular Diagnostics and Rapid Tests to Drive In-Vitro Diagnostics (IVD) Market | 22 | 1 |
| 3.6.3 Regulatory Market Drivers | 22 | 1 |
| 3.6.3.1 Emergence of Laws for Patent Protection | 22 | 1 |
| 3.6.3.2 Easing Regulations to Drive Decentralized Testing | 22 | 1 |
| 3.6.4 Social Market Drivers | 22 | 1 |
| 3.6.4.1 Paradigm Shift towards Preventive Medicine to Drive Growth in Diagnostics for Early Detection and Screening | 22 | 1 |
| 3.6.4.2 Patient Centric Medicine with Better Informed Consumers Assumes More Significant Role in Managing Their Health | 23 | 1 |
| 3.6.4.3 Ageing Population to Drive Demand for In-Vitro Diagnostic (IVD) Tests for Monitoring and Disease Detection | 23 | 1 |
| 3.7 In-Vitro Diagnostics (IVD) Market, Market Restraints | 23 | 1 |
| 3.7.1 Economic Market Restraints | 23 | 1 |
| 3.7.1.1 Healthcare Budget Deficits in the Majority of Developed Nations to Lead to Rationalization of Testing | 23 | 1 |
| 3.7.1.2 Pricing Pressures, Low Levels Of Reimbursement, Reimbursement Cuts, and Lack of Monetary Incentives for New Tests to Impede Market Growth | 23 | 1 |
| 3.7.1.3 Local Players for Consumables Put Pricing Pressures on International Players in Developing Nations | 23 | 1 |
| 3.7.2 Social Market Restraints | 24 | 1 |
| 3.7.2.1 Shortage of Skilled Labor a Major Problem for Laboratories | 24 | 1 |
| 4 Global In-Vitro Diagnostics (IVD) Market: Category Analysis and Forecasts | 25 | 30 |
| 4.1 Clinical Chemistry Market: Market Characterization | 25 | 1 |
| 4.1.1 Global Clinical Chemistry Market, Revenue ($m), 2002 2009 | 25 | 1 |
| 4.1.2 Global Clinical Chemistry Market, Revenue Forecasts ($m), 2009 2016 | 26 | 1 |
| 4.1.3 Global Clinical Chemistry Market, Company Share (%), 2008 | 27 | 1 |
| 4.1.4 Clinical Chemistry Market: Market Drivers | 28 | 1 |
| 4.1.4.1 Emerging Economies Such As India, Brazil and China Are Expected To Drive Growth in the Global Clinical Chemistry Market | 28 | 1 |
| 4.1.4.2 Need for Greater Productivity and Throughput Gains and Need for Cost Saving Will Drive Segments Such As Point of Care (POC), Rapid Tests, and Automated Analyzers | 28 | 1 |
| 4.1.4.3 Need for Integration Will Drive Purchases of Integrated Chemical Analyzers | 28 | 1 |
| 4.1.4.4 Ageing Population and Consequent Rise in the Incidence of Chronic and Infectious Diseases Will Continue To Drive Market Growth | 28 | 1 |
| 4.1.5 Clinical Chemistry Market: Market Restraints | 28 | 1 |
| 4.1.5.1 Market Maturity Is Putting Downward Pricing Pressures On Vendors | 28 | 1 |
| 4.1.5.2 Revised FDA Guidelines and Increased Compliance Expected To Adversely Impact Small Laboratories | 29 | 1 |
| 4.2 Immuno Chemistry Market: Market Characterization | 29 | 1 |
| 4.2.1 Global Immuno Chemistry Market, Revenue ($m), 2002 2009 | 29 | 2 |
| 4.2.2 Global Immuno Chemistry Market, Revenue Forecast ($m), 2009 2016 | 31 | 1 |
| 4.2.3 Global Immuno Chemistry Market, Company Share (%), 2008 | 32 | 1 |
| 4.2.4 Immuno Chemistry Market: Market Drivers | 33 | 1 |
| 4.2.4.1 Emerging Economies to Drive Growth in Global Immuno Chemistry Market | 33 | 1 |
| 4.2.4.2 Advances in Molecular Biology, Discovery of New Biomarkers and New Applications to Drive Future Growth | 33 | 1 |
| 4.2.4.3 Technological Innovations Such As Miniaturization of Biosensors, Microfluidics and Nanotechnology Leading To Development of New, Innovative Immunodiagnostic Rapid Tests | 33 | 1 |
| 4.2.4.4 Pharmacogenomics and Need for Personalized Testing to Determine Drug Response to Drive Immuno Chemistry Market in the Future | 33 | 1 |
| 4.2.4.5 Increasing Awareness of Early Screening, Detection and Diagnosis Fuelling Growth | 34 | 1 |
| 4.2.5 Immuno Chemistry Market: Market Restraints | 34 | 1 |
| 4.2.5.1 Low Reimbursement Rates Hamper the Development and Uptake of New Immunoassays | 34 | 1 |
| 4.3 Haematology Market: Market Characterization | 35 | 1 |
| 4.3.1 Global Haematology Market, Revenues ($m), 2002 2009 | 35 | 1 |
| 4.3.2 Global Haematology Market, Revenue Forecasts ($m), 2009 2016 | 36 | 1 |
| 4.3.3 Global Haematology Market, Company Share (%), 2008 | 37 | 1 |
| 4.3.4 Haematology Market: Market Drivers | 37 | 1 |
| 4.3.4.1 Brazil, India and Japan to Lead Growth in Global Haematology Market | 37 | 1 |
| 4.3.4.2 Technological advancements which aid in Miniaturization, Enhanced Menu Options and Improved Throughput Will Drive Market | 38 | 1 |
| 4.3.4.3 Adoption of Automated Analyzers in Small-to-Medium Laboratories Will Lead to Market Growth | 38 | 1 |
| 4.3.5 Haematology Market: Market Restraints | 38 | 1 |
| 4.3.5.1 Intense Competition Put Downward Pressure on Profit Margins | 38 | 1 |
| 4.4 Histology and Cytology Market: Market Characterization | 39 | 1 |
| 4.4.1 Global Histology and Cytology Market, Revenue ($m), 2002 2009 | 39 | 1 |
| 4.4.2 Global Histology and Cytology Market, Revenue Forecasts ($m), 2009 2016 | 40 | 1 |
| 4.4.3 Global Histology and Cytology Market, Company Share (%), 2008 | 41 | 1 |
| 4.4.4 Histology and Cytology Market: Market Drivers | 42 | 1 |
| 4.4.4.1 Asia Pacific and Europe to Drive Market Demand | 42 | 1 |
| 4.4.4.2 Advances in Cell/Tissue Staining, Biopsy in Cancer Detection and Diagnosis and Automation Technology Will Drive Market Growth | 42 | 1 |
| 4.4.5 Histology and Cytology Market: Market Restraints | 42 | 1 |
| 4.4.5.1 New Molecular, Non Invasive Blood Tests Threaten To Cannibalize Market for Detection of Infectious Diseases | 42 | 1 |
| 4.4.5.2 Consolidated Market Creates Entry Barriers for Small Players | 42 | 1 |
| 4.5 Microbiology Culture Market: Market Characterization | 43 | 1 |
| 4.5.1 Global Microbiology Culture Market, Revenue ($m), 2002 2009 | 43 | 1 |
| 4.5.2 Global Microbiology Culture Market, Revenue Forecasts ($m), 2009 2016 | 44 | 1 |
| 4.5.3 Global Microbiology Culture Market, Company Share (%), 2008 | 45 | 1 |
| 4.5.4 Global Microbiology Culture Market: Market Drivers | 45 | 1 |
| 4.5.4.1 High growth in China and Brazil to drive market | 45 | 1 |
| 4.5.4.2 High Prevalence of Infectious Diseases Will Sustain Market Growth In The Future | 45 | 1 |
| 4.5.4.3 Improved Efficiency, Time Savings and Lack of Skilled Labor Will Lead to Increased Adoption of Automation | 46 | 1 |
| 4.5.5 Microbiology Culture Market: Market Restraints | 46 | 1 |
| 4.5.5.1 Molecular Diagnostics Are Increasingly Replacing the Time Consuming Process of Bacterial Culture | 46 | 1 |
| 4.6 Infectious Immunology Market: Market Characterization | 47 | 1 |
| 4.6.1 Global Infectious Immunology Market, Revenue ($m), 2002 2009 | 47 | 1 |
| 4.6.2 Global Infectious Immunology Market, Revenue Forecasts ($m), 2009 2016 | 48 | 1 |
| 4.6.3 Global Infectious Immunology Market, Company Share (%), 2008 | 49 | 1 |
| 4.6.4 Global Infectious Immunology Market: Market Drivers | 49 | 1 |
| 4.6.4.1 Emergence of Highly Infectious Mutant Strains Of Pathogens Will Drive the Demand for Appropriate Diagnostics to Contain the Spread of These Agents | 49 | 1 |
| 4.6.4.2 New Cases of Humans Infected With Animal Pathogens Will Lead to High Demand for Diagnostic Tests | 50 | 1 |
| 4.6.5 Global Infectious Immunology Market: Market Restraints | 50 | 1 |
| 4.6.5.1 Reimbursement Systems That Do Not Provide Incentives to New Tests Will Hold Back Market Growth | 50 | 1 |
| 4.7 Genetic Testing Market: Market Characterization | 51 | 1 |
| 4.7.1 Global Genetic Testing Market, Revenue ($m), 2002 2009 | 51 | 1 |
| 4.7.2 Global Genetic Testing Market, Revenue Forecasts ($m), 2009 2016 | 52 | 1 |
| 4.7.3 Global Genetic Testing Market, Company Share (%), 2008 | 53 | 1 |
| 4.7.4 Global Genetic Testing Market: Market Drivers | 53 | 1 |
| 4.7.4.1 Rapid Adoption of Genetic Testing For Screening Genetic Disorders and High Risk Patients in Brazil, India and China to Drive Market | 53 | 1 |
| 4.7.4.2 Advances in Genetics and Proteomics, and Better Understanding of Underlying Genetic Causes of Diseases Will Drive Test Volumes through New Tests | 53 | 1 |
| 4.7.4.3 Rising Awareness Driven By Direct To Consumer Marketing Will Drive Market Growth | 54 | 1 |
| 4.7.4.4 Pharmacogenomic Testing To Play a Significant Role in Driving the Genetic Testing Market | 54 | 1 |
| 4.7.5 Global Genetic Testing Market: Market Restraints | 54 | 1 |
| 4.7.5.1 Prohibitive Costs for Genetic Tests Likely To Temper High Growth in Demand In The Future | 54 | 1 |
| 4.7.5.2 Lack of Standardization of Genetic Tests Creates Doubts about the Validity of Tests | 54 | 1 |
| 5 Global In-Vitro Diagnostics (IVD) Market: Country Analysis and Forecasts | 55 | 49 |
| 5.1 Global In-Vitro Diagnostics (IVD)Market: Geographic Trends Analysis | 55 | 1 |
| 5.2 Market Characterization, North America, 2002 2016 | 56 | 1 |
| 5.2.1 The US In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 56 | 1 |
| 5.2.2 The US In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 57 | 1 |
| 5.2.3 Canada In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 58 | 2 |
| 5.2.4 North America In-Vitro Diagnostics (IVD) Market, Market Drivers | 60 | 1 |
| 5.2.4.1 Ageing Population and Technological Innovation to Drive Testing Volumes | 60 | 1 |
| 5.2.4.2 Point Of Care and Satellite Laboratory Testing In Non-Traditional, Ambulatory Settings to Gain Increased Focus In The Future | 60 | 1 |
| 5.2.5 North America In-Vitro Diagnostics (IVD) Market, Market Restraints | 60 | 1 |
| 5.2.5.1 Heightened Regulatory Oversight on Personalized Testing Such As Direct to Consumer Genetic Testing To Hamper Growth of Private Players | 60 | 1 |
| 5.3 Market Characterization, Europe, 2002 2016 | 61 | 1 |
| 5.3.1 The UK In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 61 | 1 |
| 5.3.2 The UK In-Vitro Diagnostics (IVD) Market, Revenues ($m), 2009 2016 | 62 | 1 |
| 5.3.3 Germany In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 63 | 1 |
| 5.3.4 Germany In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 64 | 1 |
| 5.3.5 France In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 65 | 2 |
| 5.3.6 France In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 67 | 1 |
| 5.3.7 Italy In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 68 | 1 |
| 5.3.8 Italy In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 69 | 1 |
| 5.3.9 Spain In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 70 | 1 |
| 5.3.10 Spain In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 71 | 1 |
| 5.3.11 Belgium In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 72 | 1 |
| 5.3.12 Belgium In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 73 | 1 |
| 5.3.13 The Netherlands In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 74 | 1 |
| 5.3.14 The Netherlands In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 75 | 1 |
| 5.3.15 Europe In-Vitro Diagnostics (IVD) Market, Market Drivers | 76 | 1 |
| 5.3.15.1 Ageing Population to Drive Growth Due To Increase in Routine Testing | 76 | 1 |
| 5.3.15.2 Increasing Surveillance for Hospital Acquired Infections to Drive Screening Kits | 76 | 1 |
| 5.3.15.3 Consolidation of Laboratories to Create Opportunities in the Laboratory Automation for Managing Pre-Analytical and Post-Analytical Phases | 76 | 1 |
| 5.3.16 Europe In-Vitro Diagnostics (IVD) Market, Market Restraints | 76 | 1 |
| Healthcare Budget Deficits in the Majority of European Markets to Continue To Lead to Rationalization of Testing | 76 | 1 |
| 5.3.16.2 Purchase Organizations Will Leverage Their Position To Negotiate Low Cost Contracts, Leading To Thinning Margins. | 77 | 1 |
| 5.4 Market Characterization, Asia Pacific, 2002 2016 | 77 | 1 |
| 5.4.1 Japan In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 77 | 1 |
| 5.4.2 Japan In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 78 | 1 |
| 5.4.3 China In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 79 | 2 |
| 5.4.4 China In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 81 | 1 |
| 5.4.5 India In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 82 | 1 |
| 5.4.6 India In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 83 | 1 |
| 5.4.7 Australia In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 84 | 1 |
| 5.4.8 Australia In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 85 | 1 |
| 5.4.9 Taiwan In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 86 | 1 |
| 5.4.10 Taiwan In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 87 | 1 |
| 5.4.11 Republic of Korea In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 88 | 1 |
| 5.4.12 Republic of Korea In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 89 | 1 |
| 5.4.13 Asia Pacific In-Vitro Diagnostics (IVD) Market, Market Drivers | 90 | 1 |
| 5.4.13.1 Ageing Population Will Drive Growth in Developed Countries Such As Japan and Australia, While Population Growth Will Drive Emerging Economies | 90 | 1 |
| 5.4.13.2 Increased Technology Adoption will be a Uniform Trend Driving the Sales of IVD Instruments In the Future | 90 | 1 |
| 5.4.14 Asia Pacific In-Vitro Diagnostics (IVD) Market, Market Restraints | 91 | 1 |
| 5.4.14.1 Laboratory Consolidation to Put a Further Squeeze on the In-Vitro Diagnostics (IVD) Margins in Japan and Australia | 91 | 1 |
| 5.4.14.2 Local Players Competing with International Players by offering Cheap Products | 91 | 1 |
| 5.5 Market Characterization, South and Central America, 2002 2016 | 91 | 1 |
| 5.5.1 Brazil In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 91 | 2 |
| 5.5.2 Brazil In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 93 | 1 |
| 5.5.3 Argentina In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 94 | 1 |
| 5.5.4 Argentina In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 95 | 1 |
| 5.5.5 Mexico In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 96 | 1 |
| 5.5.6 Mexico In-Vitro Diagnostics (IVD) Market, Revenues ($m), 2009 2016 | 97 | 1 |
| 5.5.7 South and Central America In-Vitro Diagnostics (IVD) Market, Market Drivers | 98 | 1 |
| 5.5.7.1 Economic Stability in the Region to Increase Spending On Healthcare | 98 | 1 |
| 5.5.7.2 Laboratory Consolidation to Push Automation in High Volume Testing Centers | 98 | 1 |
| 5.5.8 South and Central America In-Vitro Diagnostics (IVD) Market, Market Restraints | 98 | 1 |
| 5.5.8.1 Price Sensitivity and Increasing Competition from Local Players a Growing Threat for International Players in the Region | 98 | 1 |
| 5.6 Market Characterization, Middle East and Africa, 2002 2016 | 99 | 1 |
| 5.6.1 Israel In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 99 | 1 |
| 5.6.2 Israel In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 100 | 1 |
| 5.6.3 South Africa In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2002 2009 | 101 | 1 |
| 5.6.4 South Africa In-Vitro Diagnostics (IVD) Market, Revenue ($m), 2009 2016 | 102 | 1 |
| 5.6.5 Middle East and Africa In-Vitro Diagnostics (IVD) Market, Market Drivers | 103 | 1 |
| 5.6.5.1 Rising Incidence of Drug Resistance to Lead To Growing Use of In Vitro Diagnostics to Contain Spread of Infections | 103 | 1 |
| 5.6.6 Middle East and Africa In-Vitro Diagnostics (IVD) Market, Market Restraints | 103 | 1 |
| 5.6.6.1 Lack of Affordability for Sophisticated In-Vitro Diagnostics | 103 | 1 |
| 6 Global In-Vitro Diagnostics (IVD) Market: Strategic Competitive Assessment | 104 | 16 |
| 6.1 Key Market Participants | 104 | 1 |
| 6.1.1 F. Hoffmann-La Roche Ltd | 104 | 1 |
| 6.1.1.1 Company Overview | 104 | 1 |
| 6.1.1.2 Deals Landscape | 104 | 1 |
| 6.1.1.3 Pipeline Product Portfolio | 105 | 1 |
| 6.1.2 Siemens Medical Solutions | 106 | 1 |
| 6.1.2.1 Company Overview | 106 | 1 |
| 6.1.2.2 Pipeline Product Portfolio | 107 | 1 |
| 6.1.2.3 Deals Landscape | 108 | 1 |
| 6.1.3 Abbott Laboratories | 108 | 1 |
| 6.1.3.1 Company Overview | 108 | 1 |
| 6.1.3.2 Deals Landscape | 109 | 1 |
| 6.1.3.3 Pipeline Product Portfolio | 110 | 1 |
| 6.1.4 Beckman Coulter, Inc. | 110 | 1 |
| 6.1.4.1 Company Overview | 110 | 2 |
| 6.1.4.2 Deals Landscape | 112 | 1 |
| 6.1.4.3 Pipeline Product Portfolio | 113 | 1 |
| 6.1.5 bioMerieux Sa | 113 | 1 |
| 6.1.5.1 Company Overview | 113 | 1 |
| 6.1.5.2 Deals Landscape | 114 | 1 |
| 6.1.5.3 Pipeline Product Portfolio | 114 | 1 |
| 6.1.6 Ortho-Clinical Diagnostics | 114 | 1 |
| 6.1.6.1 Company Overview | 114 | 1 |
| 6.1.6.2 Deals Landscape | 115 | 1 |
| 6.1.6.3 Pipeline Product Portfolio | 115 | 1 |
| 6.1.7 Becton, Dickinson and Company | 115 | 1 |
| 6.1.7.1 Company Overview | 115 | 1 |
| 6.1.7.2 Deals Landscape | 116 | 1 |
| 6.1.7.3 Pipeline Product Portfolio | 116 | 1 |
| 6.1.8 Bio-Rad Laboratories, Inc. | 116 | 1 |
| 6.1.8.1 Company Overview | 116 | 1 |
| 6.1.8.2 Deals Landscape | 117 | 1 |
| 6.1.9 Inverness Medical Innovations, Inc | 117 | 1 |
| 6.1.9.1 Company Overview | 117 | 1 |
| 6.1.9.2 Deals Landscape | 118 | 1 |
| 6.1.9.3 Pipeline Product Portfolio | 119 | 1 |
| 7 Global In-Vitro Diagnostics (IVD) Market: Product Pipeline Analysis | 120 | 7 |
| Pipeline Products Analysis by Category | 120 | 1 |
| 7.1.1 Pipeline Products Analysis: Immuno Chemistry Market | 121 | 1 |
| 7.1.2 Pipeline Products Analysis: Infectious Immunology | 122 | 1 |
| 7.2 Key Pipeline Products Currently Undergoing Development | 122 | 1 |
| 7.2.1 Clinical Chemistry Pipeline Products | 122 | 1 |
| 7.2.1.1 ADVIA 1800 neonatal bilirubin test | 122 | 1 |
| 7.2.2 Genetic Testing | 122 | 1 |
| 7.2.2.1 SYNCHRON Anti-dsDNA test | 122 | 1 |
| 7.2.2.2 Multiple Sclerosis-Molecular Diagnostic Test | 123 | 1 |
| 7.2.2.3 AttoSense Lupus Panel | 123 | 1 |
| 7.2.2.4 LungSentryGx-Genetic Predisposition to Lung Cancer Risk | 123 | 1 |
| 7.2.3 Haematology | 123 | 1 |
| 7.2.3.1 Clondiag HIV Molecular Device | 123 | 1 |
| 7.2.3.2 CD4Now BioChip | 123 | 1 |
| 7.2.3.3 Diagnostic Microarrays-Acute Myeloid Leukemia | 124 | 1 |
| 7.2.4 Immunochemistry | 124 | 1 |
| 7.2.4.1 Biomarkers for Alzheimer s disease | 124 | 1 |
| 7.2.4.2 Next Generation Triage CardioProfilER | 124 | 1 |
| 7.2.4.3 Triage Stroke Panel | 124 | 1 |
| 7.2.4.4 NuroPro Blood Test | 124 | 1 |
| 7.2.4.5 AmpliChip p53 Test | 124 | 1 |